News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alexion Pharmaceuticals Inc. (ALXN)'s Soliris Shows Potential for Organ Transplants


9/12/2013 8:06:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cheshire's Alexion Pharmaceuticals Inc. presented preliminary data Tuesday in Austria that it says is an encouraging sign its blockbuster drug Soliris may be a viable treatment to prevent kidney transplant rejections. The Phase 2 study seeks to evaluate Soliris as an investigational therapy to prevent acute antibody-mediated rejection, or AMR, in sensitized deceased-donor kidney transplant patients. Soliris, which is approved in a number of countries for treatment of several blood disorders, is not yet approved to prevent organ transplant rejections.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES